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**Colorectal Cancer Pattern in Latin America** {#ijc31920-sec-0001}
==============================================

Based on the 2012 GLOBOCAN database, the most common cancers in Latin America and the Caribbean were prostate, breast, cervix uteri and colorectal cancer (CRC), followed by lung and gastric cancer (combined for both sexes). A representative marker of economic development and extent of westernization in Latin American and the Caribbean States is that of the increasing incidence of CRC, which now ranks as a top five cancer in approximately 80% of its countries.[1](#ijc31920-bib-0001){ref-type="ref"}

The global burden of CRC is rising, with 2.2 million predicted new cases (and 1.1 million deaths) by 2030.[2](#ijc31920-bib-0002){ref-type="ref"} Within Latin America and the Caribbean, the highest mortality of CRC was found in Trinidad and Tobago, Uruguay, Barbados and Argentina, while the highest increasing trends in mortality were found in Brazil, Chile and Mexico.[3](#ijc31920-bib-0003){ref-type="ref"} The high rates of CRC could be associated with lifestyle behaviors, including diet, physical inactivity, overweight and obesity, but may also reflect the limited availability of screening programmes, early diagnosis and curative treatment programmes in these countries. This is the result of suboptimal organization of national health systems, as well as social, cultural and economic inequalities in these countries.[3](#ijc31920-bib-0003){ref-type="ref"}, [4](#ijc31920-bib-0004){ref-type="ref"}, [5](#ijc31920-bib-0005){ref-type="ref"}, [6](#ijc31920-bib-0006){ref-type="ref"}

CRC also represents a major health challenge in Europe. While most countries in Europe have established guidelines for the management of CRC, in which population screening plays a vital role, there are still knowledge gaps regarding improved prevention and treatment of CRC. Compared to Europe, the Latin America and Caribbean population still has a lower cumulative risk of CRC (1.6 *vs*. 3.5 for incidence and 0.8 *vs*. 1.4 for mortality, for Latin America and Caribbean *vs*. Europe, respectively), but the numbers for Latin America and Caribbean are expected to increase.[1](#ijc31920-bib-0001){ref-type="ref"}, [3](#ijc31920-bib-0003){ref-type="ref"}, [7](#ijc31920-bib-0007){ref-type="ref"} Some of the differences may be related to lower levels of reporting of CRC cases in Latin America and the Caribbean, and insufficient organization and funding of cancer registries compared to Europe and United States. Only 6% of the Latin America and the Caribbean population is covered by population‐based cancer registries, compared to 96% of the United States and 32% of the European populations.[5](#ijc31920-bib-0005){ref-type="ref"}, [8](#ijc31920-bib-0008){ref-type="ref"}

**CRC Screening and Early Detection** {#ijc31920-sec-0002}
=====================================

CRC primarily affects men and women above 50 years of age. However, recent data show that younger adults are becoming more affected in the Latin America and the Caribbean countries.[4](#ijc31920-bib-0004){ref-type="ref"}, [8](#ijc31920-bib-0008){ref-type="ref"} Effective CRC screening programs may reduce its incidence by detection and removal of precursor lesions and its mortality by early diagnosis of localized disease, when accompanied by effective diagnostic follow‐up procedures and treatment.[9](#ijc31920-bib-0009){ref-type="ref"}, [10](#ijc31920-bib-0010){ref-type="ref"} While representing a highly preventable disease, and perhaps the most preventable of cancers,[11](#ijc31920-bib-0011){ref-type="ref"}, [12](#ijc31920-bib-0012){ref-type="ref"}, [13](#ijc31920-bib-0013){ref-type="ref"}, [14](#ijc31920-bib-0014){ref-type="ref"} the majority of the Latin American countries lacks adequate systematic screening or prevention programmes. It is widely accepted that general screening of people above 50 years is a cost‐effective and efficacious way of reducing CRC.[9](#ijc31920-bib-0009){ref-type="ref"}, [10](#ijc31920-bib-0010){ref-type="ref"} From our literature research, only nine (20%) of the Latin America and the Caribbean countries have developed guidelines for early detection of CRC (Argentina, Brazil, Chile, Colombia, Cuba, Ecuador, Mexico, Puerto Rico and Uruguay), based on fecal immunochemical testing (FIT), sigmoidoscopy, or colonoscopy. Even in these countries, low adherence to the CRC guidelines remains a challenge -- as does the fact that the screening programmes are mainly covering urban areas. In contrast, 24 out of 28 European Union countries had established or were preparing to establish nationwide screening programmes in 2015.[15](#ijc31920-bib-0015){ref-type="ref"}

**Genetic Profile for Hereditary CRC: Lynch Syndrome** {#ijc31920-sec-0003}
======================================================

There is currently an incomplete picture of the risk attributable to inherited, environmental or lifestyle factors for CRC. Understanding the hereditary risk will refine the clinical management and genetic counseling of these patients and their families.

Lynch syndrome (LS) is caused by a defective mismatch repair (MMR) system due to the presence of pathogenic variants in at least one of the MMR genes (*path_MLH1, path_MSH2, path_MSH6* and *path_PMS2*) or due to deletions of the 3′ portion of the *EPCAM* gene.[16](#ijc31920-bib-0016){ref-type="ref"} However, the presence of *PMS2* pseudogenes complicates the analysis of pathogenic variants in a clinical settings, where diagnostic laboratories should apply strategies, e.g. DNA‐based or RNA‐based long‐range PCR with a forward primer in the unique *PMS2* exon 10, to detect pathogenic point variants in exons 11--15, and/or multiplex ligation‐dependent amplification (MLPA) to detect large deletions and duplications in the gene conversion region and, and/or using PCR primers based on paralogous sequence variants (PSV) to avoid sequences homologous to exons 1--5 of *PMS2*.[17](#ijc31920-bib-0017){ref-type="ref"}

Currently, patients with CRC are referred to germline MMR testing based on the identification of high‐risk phenotypic features (i.e. early age of onset, family history, clinical criteria).[18](#ijc31920-bib-0018){ref-type="ref"}, [19](#ijc31920-bib-0019){ref-type="ref"}, [20](#ijc31920-bib-0020){ref-type="ref"} Systematic screening for LS by MMR immunohistochemistry (IHC) was first included in the National Comprehensive Cancer Networking (NCCN) guidelines in 2017.[21](#ijc31920-bib-0021){ref-type="ref"} Until regional guidelines consider and adopt this systematic screening, patients with CRC in Latin America are after NCNN recommendations. This points out the awareness and capacity of physicians to identify potential LS candidates. Genetic testing for hereditary CRC patients has not been routinely used in all countries from Latin America and the Caribbean. Even in the developed world, genetic screening has not yet been fully deployed.

The diagnosis of LS has been aided by the advent of next‐generation sequencing (NGS). This technology allows clinicians to simultaneously test multiple genes with massive parallel sequencing in a cost‐effective manner. The number of genes in a panel range from two to \>100 and the use of gene panels to test for hereditary cancer syndromes became integrated into standard clinical practice starting in 2012 in developed countries,[22](#ijc31920-bib-0022){ref-type="ref"} and in some countries from Latin America, e.g. Argentina, Brazil, Uruguay and Peru. However, NGS studies have reported that as much as \~18% of patients diagnosed with CRC \< age of 50 years have pathogenic variants in genes that are not traditionally associated with CRC (*ATM*, *CHEK2*, *BRCA1*, *BRCA2*, *CDKN2A* and *PALB2*).[18](#ijc31920-bib-0018){ref-type="ref"}, [23](#ijc31920-bib-0023){ref-type="ref"} Notably, there is a need to determine whether these variants contribute to hereditary CRC risk *via* the combination of low‐ and moderate‐penetrance susceptibility alleles.[18](#ijc31920-bib-0018){ref-type="ref"}, [20](#ijc31920-bib-0020){ref-type="ref"}, [23](#ijc31920-bib-0023){ref-type="ref"}, [24](#ijc31920-bib-0024){ref-type="ref"}, [25](#ijc31920-bib-0025){ref-type="ref"}

**Cancer risks in LS** {#ijc31920-sec-0004}
----------------------

The Prospective Lynch Syndrome Database (PLSD) ([www.PLSD.eu](http://www.plsd.eu)) described that the cumulative incidence of any cancer at 70 years of age is 72% for *path_MLH1* and *path_MSH2* carriers, but lower in *path_MSH6* (52%) and *path_PMS2* (18%) carriers. *Path_MSH*6 and *path_PMS2* carriers do not have an increased risk for cancer before 40 years and 50 years of age, respectively.[26](#ijc31920-bib-0026){ref-type="ref"}, [27](#ijc31920-bib-0027){ref-type="ref"}, [28](#ijc31920-bib-0028){ref-type="ref"}

The cumulative risk for cancer in specific organs or group of organs at 75 years was: CRC: 46%, 43% and 15% in *path_MLH1*, *path_MSH2* and *path_MSH6* carriers; for endometrial cancer 43%, 57% and 46%; for ovarian cancer 10%, 17% and 13%; for upper gastrointestinal (gastric, duodenal, bile duct or pancreatic) cancers 21%, 10% and 7%; for urinary tract cancers 8%, 25% and 11%; for prostate cancer 17%, 32% and 18%; and for brain tumors 1%, 5% and 1%, respectively. Ovarian cancer occurred mainly premenopausally. By contrast, upper gastrointestinal, urinary tract and prostate cancers occurred predominantly at older ages. Overall 5‐year survival for prostate cancer was 100%, urinary bladder 93%, ureter 85%, duodenum 67%, stomach 61%, bile duct 29%, brain 22% and pancreas 0%.[28](#ijc31920-bib-0028){ref-type="ref"}

There is a significant variation in lifetime cancer risks and mean age at diagnosis in LS patients who harbor *path_MMR* variants. Therefore, genetic cancer risk assessment and counseling should be based on the affected gene, gender and age of the patient.[26](#ijc31920-bib-0026){ref-type="ref"} These studies lend support to the need to establish the genetic testing in most of the countries from Latin America in order to assess the cancer risk in these not yet studied populations. Importantly, the cancer risk is influenced by environmental factors, and one may expect different risks in different countries due to epidemiological factors.

**The spectrum of path_MMR variants** {#ijc31920-sec-0005}
-------------------------------------

A recent description of the spectrum of the *path_MMR* variants in Latin America LS families included the identification of *path\_ MLH1* variants in up to 54% of the cases, *path\_ MSH2* variants in up to 43%, *path\_ MSH6* variants in up to 10%, *path\_ PMS2* variants in up to 3%, and *path\_ EPCAM* variants in up to 0.8%.[19](#ijc31920-bib-0019){ref-type="ref"} A slightly higher contribution for *path_MLH1* variants and *path\_ MSH2* variants and lower for *path\_ MSH6* variants and *path\_ PMS2* variants was described when comparing to international reports.[19](#ijc31920-bib-0019){ref-type="ref"}, [29](#ijc31920-bib-0029){ref-type="ref"}, [30](#ijc31920-bib-0030){ref-type="ref"}

With the aim to describe a more complete *path_MMR* spectrum from Latin America, we invited 35 institutions from 14 countries to participate in a survey of MMR variants. Of these, 25 institutions from ten different countries accepted to participate and provided information about *path_MMR* variants or tumor MMR analysis. Briefly, 2,685 suspected LS families from Argentina (five centers), Brazil (six centers), Chile (one center), Colombia (two centers), Costa Rica (one center), Mexico (one centers), Peru (two centers) and Uruguay (one center) were selected to perform germline MMR genetic testing (Table [1](#ijc31920-tbl-0001){ref-type="table"}). The Amsterdam criteria (AMS) or Bethesda guidelines were mostly used to select cases for screening by IHC and/or microsatellite instability (MSI) analysis or *BRAF* sequencing. MMR deficiency was identified in 30% (774/2,552) of the cases who underwent screening analysis (Table [1](#ijc31920-tbl-0001){ref-type="table"}).

###### 

Summary of genetic testing results from LS cancer registries in Latin America

  Country      City              Latin American Institution                                                           Center type                           Suspected N Families   Clinical criteria                    Screening                                                                                  Sequenced N Famiies   Germline MMR Genetic Testing   LS families             
  ------------ ----------------- ------------------------------------------------------------------------------------ ------------------------------------- ---------------------- ------------------------------------ ------------------------------------------------------------------------------------------ --------------------- ------------------------------ ------------- ---- ---- -----
  Argentina    Buenos Aires      Hospital of Gastroenterology "Dr. C. B. Udaondo"                                     Public Hospital                       850                    AMS, Bethesda, universal screening   IHC and/or MSI, *BRAF* sequencing[1](#ijc31920-note-0004){ref-type="fn"}                   70                    17                             18            1    4    40
  Argentina    Buenos Aires      Hospital Italiano                                                                    Hereditary Cancer Reference           244                    AMS, Bethesda                        Mainly IHC[1](#ijc31920-note-0004){ref-type="fn"}                                          82                    13                             13            1    1    28
  Argentina    Buenos Aires      Centro de Educación Médica e Investigaciones Clínicas (CEMIC)                        University Hospital                   104                    AMS, Bethesda                        IHC and/or MSI[1](#ijc31920-note-0004){ref-type="fn"}                                      26                    9                              10            3    1    23
  Argentina    Rosario           Hospital Español                                                                     Private Hospital                      61                     AMS, Bethesda                        IHC and/or MSI[1](#ijc31920-note-0004){ref-type="fn"}                                      17                    3                              10            0    1    14
  Argentina    Cordoba           Hospital Privado Universitario de Cordoba                                            Private University Hospital           18                     AMS, Bethesda                        IHC and BRAF sequencing[1](#ijc31920-note-0004){ref-type="fn"}                             3                     0                              2             0    0    2
  Brazil       Barretos          Barretos Cancer Hospital                                                             Cancer Register Hospital              510                    AMS, Bethesda, universal screening   IHC and/or MSI, *BRAF* sequencing and methylation[1](#ijc31920-note-0004){ref-type="fn"}   165                   29                             25            10   7    71
  Brazil       Bahia, Amazonas   Universidade Federal da Bahia, CLION, ONCOCLIN                                       Public University, Private Hospital   28                     AMS, Bethesda                        IHC[1](#ijc31920-note-0004){ref-type="fn"}                                                 14                    2                              2             2    0    6
  Brazil       Porto Alegre      Hospital das Clinicas                                                                Public Hospital                       18                     AMS, Bethesda                        na                                                                                         na                    8                              3             0    na   11
  Brazil       Sao Paulo         Sirio Libanes Hospital                                                               Private Hospital                      63                     AMS                                  IHC[1](#ijc31920-note-0004){ref-type="fn"}                                                 51                    12                             13            2    8    35
  Brazil       Sao Paulo         A.C. Camargo Cancer Center                                                           Private Hospital                      na                     AMS, Bethesda                        IHC and/or MSI                                                                             173                   28                             20            6    1    55
  Brazil       Sao Paulo         Hospital São Paulo of the UNIFESP                                                    University Hospital                   95                     Bethesda                             IHC                                                                                        95                    11                             6             5    0    22
  Chile        Santiago          Clinica Las Condes                                                                   Private Hospital                      107                    AMS, Bethesda, universal screening   Mainly IHC[1](#ijc31920-note-0004){ref-type="fn"}                                          80                    18                             9             0    3    30
  Colombia     Ibague            Universidad de Tolima                                                                Public University                     59                     AMS, Bethesda                        Mainly IHC[1](#ijc31920-note-0004){ref-type="fn"}                                          48                    1                              6             0    0    7
  Colombia     Bogota            Clinica del Country                                                                  Private Hospital                      10                     AMS                                  Not                                                                                        4                     0                              1             0    1    2
  Costa Rica   San Jose          Hospital Dr. Rafael Angel Calderón Guardia                                           Public Hospital                       4                      AMS, Bethesda                        Not                                                                                        na                    0                              1             0    0    1
  Mexico       Mexico City       National Cancer Institute                                                            Public National Reference             43                     AMS                                  IHC[1](#ijc31920-note-0004){ref-type="fn"}                                                 10                    4                              1             0    0    5
  Peru         Lima              Universidad de San Martin de Porres                                                  Private University                    26                     AMS, Bethesda                        IHC and/or MSI[1](#ijc31920-note-0004){ref-type="fn"}                                      25                    15                             1             0    0    16
  Peru         Lima              Instituto de Investigacion Genomica                                                  Private Hospital                      6                      Family history                       Not                                                                                        6                     1                              0             1    1    3
  Uruguay      Montevideo        Grupo Colaborativo Uruguayo ‐ Investigación de afecciones oncológicas hereditarias   Hereditary Cancer Reference           439                    AMS, Bethesda                        MSI[1](#ijc31920-note-0004){ref-type="fn"}                                                 183                   18                             11            3    3    35
  Total (n)                                                                                                                                                 2,685                                                                                                                                                  1,052                 189                            152           34   31   406

Abbreviations: LS, Lynch syndrome; MMR, mismatch repair; Path_MMR, Pathogenic (disease‐causing) variant of an MMR gene; path_MLH1, pathogenic variant of the *MLH1* gene; path\_*MSH2*, pathogenic variant of the MSH2 gene; *path_MSH6*, pathogenic variant of the *MSH6* gene; *path_PMS2*, pathogenic variant of the *PMS2* gene; na, not available; CLION, Clínica de Oncologia/grupo; ONCOCLIN, Clínica Oncológica; UNIFESP, Universidade Federal de São Paulo; AMS, Amsterdam criteria; IHC, immunohistochemistry; MSI, microsatellite instability analysis.

Tumor screening applied to select suspected families for the germline MMR genetic test.

In total, 1,052 families were sequenced, and on average 39% (406/1052) carried a *path_MMR* variant, albeit with large variation between countries, ranging from 8% families in Uruguay and Argentina to 60% in Peru (Table [1](#ijc31920-tbl-0001){ref-type="table"}, Fig. [1](#ijc31920-fig-0001){ref-type="fig"}). The mean age of cancer diagnosis of 41 years (range 30--51) was described for *path_MMR* carriers (data not shown). Interestingly, 39%--80% of the families not being identified for the presence of a *path_MMR* variant actually met both the clinical criteria for LS and had an MMR deficiency. This point highlights the challenge associated with using family history for detecting families with *path_MMR* variant.[31](#ijc31920-bib-0031){ref-type="ref"} Our data support the recommendation on the application of population‐based screening protocols for all CRC and endometrial cancers diagnosed below age 70 using IHC of the MMR proteins.[31](#ijc31920-bib-0031){ref-type="ref"}, [32](#ijc31920-bib-0032){ref-type="ref"}, [33](#ijc31920-bib-0033){ref-type="ref"} Nonetheless, patients with a young age of onset and/or a positive family history of LS‐associated cancers without an identified *path_MMR* variant, may suggest the involvement of pathogenic variants in as yet undiscovered genes.[34](#ijc31920-bib-0034){ref-type="ref"}

![Percentage of LS families from the total LS suspected families in Latin American countries. The percentage for each country was obtained by a weighted sum of percentages over all its participating centers. The weight for a center was: weight = (number of LS suspected families in the center)/(total number of LS suspected families in the respective country). \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-145-318-g001){#ijc31920-fig-0001}

Based on this large cohort, the spectrum of *path_MLH1* include variants from Argentina (41%), Brazil (42%), Chile (60%), Colombia (12%), Mexico (80%), Peru (82%) and Uruguay (51%), while *path_MSH2/EPCAM* include Argentina (47%), Brazil (34%), Chile (30%), Colombia (81%), Mexico (20%), Peru (5%) and Uruguay (31%). So far, Costa Rica has described only one case harboring a widely known *path_MSH2* located on intron 5 (c.942 + 3A \> T). Importantly, the spectrum of *path_MSH6* were most frequently described in Brazil (15%) followed by Uruguay (9%), Peru (6%) and Argentina (3%), while the *path_PMS2* variants were found in Chile (10%), Brazil and Uruguay (9%, each), Argentina (8%), Colombia (7%) and Peru (6%) (Fig. [2](#ijc31920-fig-0002){ref-type="fig"}). The high prevalence of the *path_MSH6* in Brazilian population (15%) may be taken as an argument for the surveillance and follow‐up for the patients and their families. In this regard, PLSD describes a cumulative risk at 75 years for CRC of 15%; for endometrial cancer of 46%; for ovarian cancer of 13% and for prostate cancer of 18% in *path_MSH6* carriers.[28](#ijc31920-bib-0028){ref-type="ref"}

![Spectrum of *path_MMR* in Latin American countries. The percentage for each country was obtained by a weighted sum of percentages over all its participating centers. The weight for a center was: weight = (number of LS suspected families in the center)/(total number of LS suspected families in the respective country). \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-145-318-g002){#ijc31920-fig-0002}

When we analyzed data from tumor MMR analysis of 547 suspected LS cases for which further genetic testing was not available, MMR deficiency was present in 54% (296/547) of the cases (Table [2](#ijc31920-tbl-0002){ref-type="table"}). Keeping in line with the above estimates, we could expect approximately 100 cases with a *path_MMR* variant. Unfortunately, genetic services are still underdeveloped across Latin America, and access to genetic testing and counseling is very limited in the region.[35](#ijc31920-bib-0035){ref-type="ref"}, [36](#ijc31920-bib-0036){ref-type="ref"}

###### 

Summary of tumor MMR screening from the participating centers where germline genetic MMR testing is not available yet

  Country    City          Center                                           Suspected LS cases   Clinical criteria           Tumor screening   MMR deficient   MMR nondeficient
  ---------- ------------- ------------------------------------------------ -------------------- --------------------------- ----------------- --------------- ------------------
  Bolivia    La Paz        Centro de Enfermedades Neoplasicas Oncovida      61                   AMS                         MSI               3               58
  Colombia   Bogota        Fundacion Santa Fe                               209                  AMS, younger \<60 years     MSI               160             49
  Colombia   Medellin      Universidad de Antioquia                         43                   AMS, Bethesda, \<45 years   MSI               14              29
  Paraguay   Asuncion      GenPat                                           46                   na                          IHC               11              35
  Peru       Lima          Instituto Nacional de Enfermedades Neoplásicas   132                  AMS, Bethesda               IHC and/or MSI    61              71
  Peru       Lima          Oncosalud                                        3                    AMS                         IHC               1               2
  Mexico     Mexico City   Instituto Nacional de Cancerología de México     53                   AMS, Bethesda               IHC               46              7

Abbreviations: LS, Lynch syndrome; MMR, mismatch repair; AMS, Amsterdam criteria; IHC, immunohistochemistry; MSI, microsatellite instability analysis.

Some of the barriers that most of these countries are facing include a limited number of adequately trained health care professionals to perform cancer risk assessment (i.e. genetic counseling *per se* is not recognized as a profession), a high cost of genetic tests and lack of insurance coverage for such genetic tests. Furthermore, the lack of supportive healthcare policies, limited awareness about hereditary cancer and its risk by patients and physicians, few educational opportunities in cancer genetics, and the lack of infrastructure constitute some of the challenges for Latin America. Aside from these, most of the existing programs from public or private hospitals are located in large urban areas, making them practically inaccessible to people living in rural regions.[36](#ijc31920-bib-0036){ref-type="ref"}

**Founder path_MMR variants** {#ijc31920-sec-0006}
-----------------------------

Founder pathogenic variants in CRC predisposition genes appear to be less well studied when compared to breast cancer in several Latin American populations.[37](#ijc31920-bib-0037){ref-type="ref"} We recently identified 16 internationally well‐known founder MMR variants in Brazil, Colombia, Argentina, Uruguay and Chile.[19](#ijc31920-bib-0019){ref-type="ref"} The *MLH1 c.1039‐8T_1558 + 896Tdup* and the *MSH2 c.2185_2192del7insCCCT* variants have been suggested to have their origin in Colombia and Amerindian populations, respectively. No reports on founder pathogenic variants in individuals from Peru, Paraguay, Bolivia and other Latin America countries have been identified.

Importantly, further studies analyzing large series of these families in different geographic regions will be necessary to accurately estimate the prevalence and the relevance of these variants in these populations. The Latin America and Caribbean population is the result of interethnic crossing between European ancestry, African slaves and the autochthonous Amerindians, but the proportions may vary between countries. For instance, European ancestry predominates in Uruguay and Argentina, whereas Brazil includes a more heterogeneous population, which is the result of interethnic crosses between the European colonizers (mainly Portuguese), African slaves and the autochthonous Amerindians.[38](#ijc31920-bib-0038){ref-type="ref"} The Peruvian population is a multi‐ethnic population with Amerindian (45%), Mestizo (37%) and white Spanish influence (15%), along with the presence of other minority ethnic groups, such as African American, Japanese and Chinese (3%). In Colombia, Chile and Bolivia, Spanish colonists and American Indian ancestry influence the populations. Typically, Caribbean Hispanics have higher percentages of African ancestry than Argentinians and Uruguay nationals, who are predominantly of European descent.[19](#ijc31920-bib-0019){ref-type="ref"} Founder mutations provide a cost‐effective molecular diagnostic approach with the benefit of unambiguous results, and thereby do not demand highly skilled professional training.[19](#ijc31920-bib-0019){ref-type="ref"}

**Latin American Hereditary CRC Collaborative Research Network and Educational Programs** {#ijc31920-sec-0007}
=========================================================================================

Several CRC initiatives are ongoing in Latin America and Caribbean, regarding multidisciplinary research, innovation and networking. With the mission of improving teaching and research into hereditary cancer and encouraging national and international collaboration, the Brazilian Hereditary Tumors Study Group (GBETH) was set up in 2003. In 2005 and 2007, the group published two books with updates on hereditary cancer. After this, professionals from other Latin American countries began to show interest in joining the group. As a result, in 2006 GBETH changed its name to Hereditary Tumors Study Group (GETH) ([www.geth.org.br](http://www.geth.org.br)). This initiative led to the inclusion of professionals from throughout the South and Latin American continent. In 2004, the Regional Collaborative Group of the Americas (CGA) meeting was held in Argentina; two years later, the Annual CGA and the First International Symposium was organized in Brazil with the aim to set up a collaborative hereditary cancer register (the South American Hereditary Cancer Register) and to consolidate the research all over the continent.[39](#ijc31920-bib-0039){ref-type="ref"} Subsequent scientific international meetings were undertaken, of which one served as a base for the 6th Biennial Meeting of the International Society for Gastrointestinal Hereditary in Tumors (InSIGHT) in São Paulo.[40](#ijc31920-bib-0040){ref-type="ref"} This work remains being developed, and this year, the fifth annual Latin‐American Symposium in endoscopy, ENDOSUR, will be held in Santiago. For the first time, a Latin American Symposium on CRC screening will accompany it (Table [3](#ijc31920-tbl-0003){ref-type="table"}).

###### 

Scientific International meetings in Latin America

  Meeting                                                                                             Year   Institution/Society   City                  Country
  --------------------------------------------------------------------------------------------------- ------ --------------------- --------------------- -----------
  Regional CGA Meeting                                                                                2004   CGA                   Buenos Aires          Argentina
  Annual CGA Meeting                                                                                  2006   CGA                   Sao Paulo             Brazil
  First International Symposium                                                                       2006   AC Camargo/GETH       Sao Paulo             Brazil
  Regional CGA Meeting                                                                                2008   CGA                   Santiago              Chile
  I Latin American Congress of Human Genetics and IX Colombian Congress of Genetics                   2008   ACGH                  Cartagena de Indias   Colombia
  Regional CGA Meeting                                                                                2010   CGA                   Buenos Aires          Argentina
  Regional CGA Meeting                                                                                2012   CGA                   Santiago              Chile
  I International Congress of Molecular Biology in Breast and Colon Cancer: Diagnosis and Treatment   2012   UNMSM                 Lima                  Peru
  Regional CGA Meeting                                                                                2014   CGA                   Sao Paulo             Brazil
  South American Workshop of Hereditary Cancer                                                        2014   Sirio Libanes/GETH    Sao Paulo             Brazil
  InSIGHT                                                                                             2015   InSIGHT               Sao Paulo             Brazil
  V Latin American Symposium on Hereditary Syndromes in conjunction with CGA                          2018   ENDOSUR               Santiago              Chile

Abbreviations: CGA, Collaborative Group of the Americas; GETH, Hereditary Tumors Study Group; ACGH, Colombian Association of Human Genetics; UNMSM, Universidad Nacional Mayor de San Marcos; ENDOSUR, Latin‐American Symposium in endoscopy.

Likewise, in 2013, a multidisciplinary group of professionals with expertise in hereditary cancer syndromes developed a pioneering initiative in Latin America, which consisted of the creation of an e‐learning course in cancer genetic counseling. This work was developed by the joint efforts of different professionals belonging to Clínica Las Condes, Universidad del Desarrollo, Pontificia Universidad Católica de Chile and Kaiser Permanente (USA). The goal was to provide specialized training to oncology professionals, and improve the care of high‐risk patients in this region of the world. To date, the 39 students who completed this e‐learning course in cancer genetic counseling have already been applying their knowledge in order to improve the care of high‐risk patients and families in Latin America.

Regarding hereditary cancer registries in Latin America and Caribbean, there remains no national hereditary or familial cancer registers in these countries. With the mission to implement a national registry of families and the coverage of every jurisdiction of Argentina, an Argentinian Hereditary and Familial Cancer Program (PROCAFA) was created under the coordination of the National Cancer Institute of Argentina in 2011 ([https://bit.ly/2r4eeD6](https://outlook.ous-research.no/owa/redir.aspx?C=Lqir1yWRAWlqYrK4s8z8yuf8But-pZAUYpjSBqIg_n-Pnfer3h_WCA..&URL=https%3a%2f%2fbit.ly%2f2r4eeD6)). The main goals are improving detection, prevention and management of high risk cancer population in the country. The existence of a governmental hereditary cancer program in a country as big and heterogeneous as Argentina is a challenging pioneering initiative in Latin America.

This whole process of network construction and research development on hereditary cancer in Latin America prepares the ground for global Latin American collaborations on increasing the knowledge of MMR variants in different populations and to bring additional awareness of this condition to medical professionals and public health leaders in this region. Since its inception, more than ten international scientific publications have been generated in hereditary CRC by our network.[19](#ijc31920-bib-0019){ref-type="ref"}, [39](#ijc31920-bib-0039){ref-type="ref"}, [40](#ijc31920-bib-0040){ref-type="ref"}, [41](#ijc31920-bib-0041){ref-type="ref"}, [42](#ijc31920-bib-0042){ref-type="ref"}, [43](#ijc31920-bib-0043){ref-type="ref"}, [44](#ijc31920-bib-0044){ref-type="ref"}, [45](#ijc31920-bib-0045){ref-type="ref"}, [46](#ijc31920-bib-0046){ref-type="ref"}, [47](#ijc31920-bib-0047){ref-type="ref"}, [48](#ijc31920-bib-0048){ref-type="ref"} Furthermore, Argentina, Uruguay and Chile have initiated their participation on the PLSD,[26](#ijc31920-bib-0026){ref-type="ref"}, [27](#ijc31920-bib-0027){ref-type="ref"}, [28](#ijc31920-bib-0028){ref-type="ref"} providing information of a total of 128 prospective *path_MMR* carriers to enrich the global database of variation. Importantly, international multicenter collaborations are needed to enhance representation from all the countries of Latin America. We welcome other parties to join us to contribute in future studies.

**Conclusion** {#ijc31920-sec-0008}
==============

CRC is the third most common cancer in Latin America and Caribbean and the most frequent cancer affecting both genders. The geographic variations rates observed within the region are probably due to differences in the prevalence of obesity, physical inactivity, diet, as well as early detection program and health care infrastructure. Limitations on genetic testing have an impact in the evaluation of the patients at risk of hereditary CRC and their relatives, and ultimately increases the burden of cancer for this minority population. Still, existing countries where germline genetic testing is not available. However, in an effort to strengthen capacity by stimulating research, developing networks, delivering training and education, we have provided a broader genetic profile characterizing 406 LS families coming from 2,685 suspected LS. Our data provides an estimation and sensitivity of the current clinical criteria and screening methods used to analyze suspected LS cases in Latin America and Caribbean. For the first time, we described the spectrum of *path_MMR* across the countries, e.g. *path_MLH1* variants were most commonly identified in Peru (82%) and Mexico (80%), *path_MSH2/EPCAM* variants in Colombia (83%) and Argentina (47%). *Path_MSH6* and *path_PMS2* variants were the less common variants, but they showed important presence in Brazil (15%) and Chile (10%), respectively. We aim to strengthen this work further, through collaborative projects for research, the organization and upkeep of new hereditary cancer registries, arranging regional meetings and other regional efforts in this continent. Thus, the main challenges for Latin American countries are: (a) increase awareness of the population and health care professionals about hereditary cancer; (b) enhance training both for MDs and non‐MDs in genetic cancer risk assessment; (c) develop guidelines for risk assessment, cancer screening and genetic testing for these conditions; (d) implement genetic testing for patients from both private and public health care systems.
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